title: [Clinico-pathogenetic substantiation of the immunocorrective treatment of pyelonephritis in infants].
abstract: The results of the treatment of 47 babies treated with the immunocorrecting drugs (t-activin, levamisole, sodium nucleinate, prodigiozan, lysozyme) together with antimicrobial remedies are described. The babies were selected from 120 patients suffering from pyelonephritis. Indications for use of the immunomodulators included the deficiency of the T component of immunity, of phagocytosis and, more rarely, of B lymphocytes, an unfavourable premorbed condition, severe lingering disease course as well as low efficacy of antibacterial therapy. Two control groups consisted of 120 patients who were not given the immunocorrecting remedies and 30 normal children of the first year of life. The immunostimulation therapy minimized the duration of the active phase of pyelonephritis, decreasing the rate of relapses and the probability that the disease may progress to a chronic course. The positive influence of the above drugs on the clinical picture of pyelonephritis enabled the duration of antibacterial therapy, the dosage and the frequency of antibiotic use to be reduced. The favourable outcome of pyelonephritis was followed by gradual normalization of the immunological parameters.
authors.forename: V I
authors.initials: VI
authors.lastname: Kirillov
mesh_terms: D000276:Adjuvants, Immunologic; D004359:Drug Therapy, Combination; D004756:Enterobacteriaceae Infections / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000150:complications / Q000188:drug therapy*; D007223:Infant; D007231:Infant, Newborn; D007978:Levamisole / Q000008:administration & dosage*; D009696:Nucleic Acids / Q000008:administration & dosage*; D010455:Peptides / Q000008:administration & dosage*; D011135:Polysaccharides, Bacterial / Q000008:administration & dosage*; D011354:Prodigiozan / Q000008:administration & dosage*; D011704:Pyelonephritis / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D013949:Thymus Extracts / Q000008:administration & dosage*
chemical_list: D000276:Adjuvants, Immunologic; D009696:Nucleic Acids; D010455:Peptides; D011135:Polysaccharides, Bacterial; D013949:Thymus Extracts; D007978:Levamisole; C036191:T-activin; C013683:sodium nucleinate; D011354:Prodigiozan
vernacular_title: Kliniko-patogeneticheskoe obosnovanie immunokorrigiruiushcheĭ terapii pielonefrita u deteĭ rannego vozrasta.